Target

Target designates the specific biological entity including protein, nucleic acid, or biological pathway that therapeutic agents interact with to produce desired effects, representing the molecular basis for drug action and serving as focal point for discovery, development, and mechanistic understanding. Targets encompass diverse molecular classes including receptors mediating cellular signalling, enzymes catalysing biochemical reactions, ion channels controlling membrane potential, and nucleic acids regulating gene expression. Target selection profoundly influences development success, with ideal targets exhibiting disease relevance, druggability, safety profiles enabling therapeutic windows, and validation evidence supporting causal disease roles.

The biopharmaceutical industry invests extensively in target identification and validation establishing disease connections justifying therapeutic programmes. Target discovery employs genomics identifying disease-associated genes, proteomics revealing differential protein expression, pathway analysis uncovering disease mechanisms, and phenotypic screening discovering targets through functional effects. Validation demonstrates target modulation affects disease processes through genetic manipulation, pharmacological tools, or biomarker correlation with clinical outcomes. Druggability assessment evaluates whether targets offer suitable binding sites and feasibility achieving sufficient selectivity. Safety consideration examines target expression in normal tissues, physiological roles, and potential on-target toxicities. As technologies advance enabling genome-wide target exploration and understanding deepens regarding disease mechanisms, target selection becomes increasingly sophisticated supporting development programmes with higher probability of delivering safe, effective therapeutics.